Phase 1 Evaluation of <sup>11</sup>C-CS1P1 to Assess Safety and Dosimetry in Human Participants.
Matthew R. Brier, Mahdjoub Hamdi, Jayashree Rajamanikam, Haiyang Zhao, Syahir Mansor, Lynne A. Jones, Farzaneh Rahmani, Saurabh Jindal, Deborah Koudelis, Joel S. Perlmutter, Dean F. Wong, Michael L. Nickels, Joseph E. Ippolito, Robert J. Gropler, Thomas H. Schindler, Richard Laforest, Zhude Tu, Tammie L.S. Benzinger
Abstract
C-CS1P1 for evaluation of inflammation in human clinical populations. Dosimetry permits repeated measures in the same participants. Brain uptake correlates well with known target topography.
Topics & Concepts
DosimetryMedicineNuclear medicineBiodistributionS1PR1Adverse effectPharmacologyInternal medicineChemistryVEGF receptorsVascular endothelial growth factor AIn vitroVascular endothelial growth factorBiochemistrySphingolipid Metabolism and SignalingMultiple Sclerosis Research StudiesEndoplasmic Reticulum Stress and Disease